Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

Gastroenterology

Volumn 130, Issue 7, 2006, Pages 2039-2049

  Sherman, Morris ^a   Yurdaydin, Cihan ^b   Sollano, Jose ^c   Silva, Marcelo ^d   Liaw, Yun Fan ^e   Cianciara, Janusz ^f   Boron Kaczmarska, Anna ^g   Martin, Paul ^h   Goodman, Zachary ⁱ   Colonno, Richard ^j   Cross, Anne ^j   Denisky, Gail ^j   Kreter, Bruce ^j   Hindes, Robert ^j  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b ANKARA UNIVERSITY   (Turkey)

^c UNIVERSITY OF SANTO TOMAS   (Philippines)

^d UNIVERSIDAD AUSTRAL   (Argentina)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

^g POMERANIAN MEDICAL UNIVERSITY   (Poland)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^j BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLECYSTITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; GENOTYPE; HEADACHE; HEPATITIS B; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SAFETY; SEPTIC SHOCK; SIDE EFFECT; SPLEEN TUMOR; SUBSTITUTION REACTION; UPPER RESPIRATORY TRACT INFECTION; VIROLOGY; VIRUS INFECTION; VIRUS LOAD;

EID: 33744531146     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.04.007     Document Type: Article

References (39)

1. Lai C.L., Ratziu V., Yuen M.F., and Poynard T. Viral hepatitis B. Lancet 362 (2004) 2089-2093
2. Lee W.M. Hepatitis B virus infection. N Engl J Med 337 (1997) 1733-1745
3. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., and Chen C.J. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroentrology 130 (2006) 678-686
4. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., Huang G.T., and Iloeje U.H. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
5. Liaw Y.F., Leung N., Guan R., Lau G.K.K., Merican I., McCaughan G., Gane E., Kao J.H., Omata M., and Asian-Pacific consensus update working party on chronic hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B. a 2005 update. Liver Int 25 (2005) 472-489
6. Locarnini S. Hepatitis B viral resistance. mechanisms and diagnosis. J Hepatol 39 (2003) S124-S132
7. Lai C.L., Dienstag J., Schiff E., Leung N.W.Y., Atkins M., Hunt C., Brown N., Woessner M., Boehme R., and Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36 (2003) 687-696
8. Leung N.W.Y., Lai C.L., Chang T.T., Guan R., Lee C.M., Ng K.Y., Lim S.G., Wu P.C., Dent J.C., Edmundson S., Condreay L.D., and Chien R.N. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates. results after 3 years of therapy. Hepatology 33 (2001) 1527-1532
9. Liaw Y.F., Leung N.W.Y., Chang T.T., Guan R., Tai D.I., Ng K.Y., Chien R.N., Dent J., Roman L., Edmundson S., and Lai C.L. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119 (2000) 172-180
10. Leung N.W.Y. Clinical experience with lamivudine. Semin Liver Dis 22 Suppl 1 (2002) 15-21
11. Chen C.H., Lee C.M., Lu S.N., Wang J.H., Tung H.D., Hung C.H., Chen W.J., and Changchien C.S. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol 41 (2004) 454-461
12. Lok A.S.F., and McMahon B.J. Chronic hepatitis B. Hepatology 34 (2001) 1225-1241
13. Lok A.S.F., Heathcote E.J., and Hoofnagle J.H. Management of hepatitis B. 2000-summary of a workshop. Gastroenterology 120 (2001) 1828-1853
14. Ono-Nita S.K., Kato N., and Shiratori Y. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance. a study by in-vitro full-length viral DNA transfection. Hepatology 29 (1999) 939-945
15. Yeh C.T., Chien R.N., Chu C.M., and Liaw Y.F. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 31 (2000) 1318-1326
16. Bock C.T., Tillman H.L., Torresi J., Klempnauer J., Locarnini S., Manns M.P., and Trautwein C. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 122 (2002) 264-273
17. Lai C.L., Chien R.N., Leung N.W.Y., Chang T.T., Guan R., Tai D.I., Ng K.Y., Wu P.C., Dent J.C., Barber J., Stephenson S.L., and Gray D.F. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339 (1998) 61-68
18. Lau D.T.Y., Khokhar M.F., Doo E., Ghany M., Herion D., Park Y., Kleiner D.E., Schmid P., Condreay L.D., Gauthier J., Kuhns M.C., Liang T.J., and Hoofnagle J.H. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32 (2000) 828-834
19. Liaw Y.F., Chien R.N., Yeh C.T., Tsai S.L., and Chu C.M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30 (1999) 567-572
20. Papatheodoridis G.V., Dimou E., Laras A., Papadimitropoulos V., and Hadziyannis S.J. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 36 (2002) 219-226
21. Chang T.T., Lai C.L., Chien R.N., Guan R., Lim S.G., Lee C.M., Ng K.Y., Nicholls G.J., Dent J.C., and Leung N.W.Y. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 19 (2004) 1276-1282
22. Lok A.S.F., Lai C.L., Leung N., Yao G.B., Cui Z.Y., Schiff E.R., Dienstag J.L., Heathcote E.J., Little N.R., Griffiths D.A., Gardner S.D., and Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
23. Dienstag J.L., Goldin R.D., Heathcote E.J., Hann H.W.L., Woessner M., Stephenson S.L., Gardner S., Gray D.F., and Schiff E.R. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
24. Liaw Y.F., Chien R.N., and Yeh C.T. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 9 (2004) 257-262
25. Di Marco V., Di Stefano R., Ferraro D., Almasio P.L., Bonura C., Giglio M., Parisi P., Cappello M., Alaimo G., and Craxi A. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther 10 (2005) 431-439
26. Andreone P., Gramenzi A., Cursaro C., Biselli M., Camma C., Trevisani F., and Bernardi M. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 11 (2004) 439-442
27. Chang T.T., Hadziyannis S., Cianciara J., Rizzetto M., Schiff E.R., Pastore G., Bacon B., Poynard T., Rutkiewicz V., Thomas N., Denisky G., and Joshi S. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129 (2005) 1198-1209
28. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., Kiernan T.W., and Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 (1981) 431-435
29. Tenney D.J., Levine S.M., Rose R.E., Walsh A.W., Weinheimer S.P., Discotto L., Plym M., Pokornowski K., Yu C.F., Angus P., Ayres A., Bartholomeusz A., Sievert W., Thompson G., Warner N., Locarnini S., and Colonno R.J. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 48 (2004) 3498-3507
30. Levine S., Hernandez D., Yamanaka G., Zhang S., Rose R., Weinheimer S., and Colonno R.J. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 46 (2002) 2525-2532
31. Colonno R.J., Rose R., Levine S., Baldick J., Pokornowski K., Plym M., Yu C., Mazzucco C., Fang J., Hsu M., Walsh A., Eggers B., Thiry A., and Tenney D. Entecavir two year resistance update. no resistance observed in nucleoside naïve patients and low frequency resistance emergence in lamivudine refractory patients. Hepatology 42 Suppl 1 (2005) 573A
32. Peters M.G., Hann H.W., Martin P., Heathcote E.J., Buggisch P., Rubin R., Bourliere M., Kowdley K., Trepo C., Gray D.F., Sullivan M., Kleber K., Ebrahimi R., Xiong S., Brosgart C.L., and GS-00-561 Study Group. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126 (2004) 91-101
33. Perrillo R., Hann H.W., Mutimer D., Willems B., Leung N., Lee W.M., Moorat A., Gardner S., Woessner M., Bourne E., Brosgart C.L., and Schiff E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant virus. Gastroenterology 126 (2004) 81-90
34. Ganem D., and Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
35. Lok A.S.F., and McMahon B. Chronic hepatitis B. update of recommendations. Hepatology 39 (2004) 857-861
36. Innaimo S.F., Seifer M., Bisacchi G.S., Standring D.N., Zahler R., and Colonno R.J. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 41 (1997) 1444-1448
37. Ono S.K., Kato N., Shiratori Y., Kato J., Goto T., Schinazi R.F., Carrilho F.J., and Omata M. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 107 (2001) 449-455
38. Colonno R.J., Rose R., Levine S.M., Pokornowski K., Plym M., Yu C.F., Baldick C.J., Zhang S., Walsh A.W., Mazzucco C., Discotto L., Fang J., and Tenney D.J. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II and III studies is only observed in lamivudine-refractory patients. Hepatology 40 Suppl 1 (2004) 661A
39. Yuen M.F., Yuan H.J., Sablon E., Wong D.K.H., Chan A.O.O., Wong B.C.Y., and Lai C.L. Long-term follow-up study of Chinese patients with YMDD mutations. significance of hepatitis B virus genotypes and characteristics of biochemical flares. J Clin Microbiol 42 (2004) 3932-3936